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Paradoxical Association of Smoking With In-Hospital Mortality Among
Patients Admitted With Acute Ischemic Stroke
Syed F. Ali, MD; Eric E. Smith, MD, MPH, FRCP(C), FAHA; Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC;
Gregg C. Fonarow, MD, FAHA; Lee H. Schwamm, MD, FAHA
Background-—Compared to those who never smoked, a paradoxical effect of smoking on reducing mortality in patients admitted
with myocardial ischemia has been reported. We sought to determine if this effect was present in patients hospitalized with
ischemic stroke.
Methods and Results-—Using the local Get with the Guidelines-Stroke registry, we analyzed 4305 consecutively admitted ischemic
stroke patients (March 2002–December 2011). The sample was divided into smokers versus nonsmokers. The main outcome of
interest was the overall inpatient mortality. Compared to nonsmokers, tobacco smokers were younger, more frequently male and
presented with fewer stroke risk factors such as hypertension, hyperlipidemia, diabetes, coronary artery disease, and atrial
ﬁbrillation. Smokers also had a lower average NIH Stroke Scale (NIHSS) and fewer received tissue plasminogen activator (tPA).
Patients in both groups had similar adherence to early antithrombotics, dysphagia screening prior to oral intake, and deep vein
thrombosis (DVT) prophylaxis. Smoking was associated with lower all-cause in-hospital mortality (6.6% versus 12.4%; unadjusted
OR 0.46; CI [0.34 to 0.63]; P<0.001). In multivariable analysis, adjusted for age, gender, ethnicity, hypertension, diabetes mellitus,
hyperlipidemia, CAD, atrial ﬁbrillation, NIHSS, and tPA, smoking remained independently associated with lower mortality (adjusted
OR 0.64; CI [0.42 to 0.96]; P=0.03).
Conclusions-—Similar to myocardial ischemia, smoking was independently associated with lower inpatient mortality in acute
ischemic stroke. This effect may be due to tobacco-induced changes in cerebrovascular vasoreactivity, or may be due in part to
residual confounding. Larger, multicenter studies are needed to conﬁrm the ﬁnding and the effect on 30-day and 1-year mortality.
( J Am Heart Assoc. 2013;2:e000171 doi: 10.1161/JAHA.113.000171)
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T he term “smoker’s paradox” was ﬁrst introduced intoscientiﬁc discourse more than 25 years ago following
observations that smokers (in comparison to nonsmokers)
experience decreased mortality following an acute myocardial
infarction (AMI).1–4 The smoker’s paradox is one of several
reported paradoxes in the cardiovascular literature. Other
major paradoxes assessing the association of a vascular risk
factor with health outcomes after a cardiovascular event
include the obesity paradox and the gender paradox. The
obesity paradox identiﬁes a decrease in morbidity and
mortality with increasing body mass index (BMI) while the
gender paradox identiﬁes the purportedly protective associ-
ation with male gender.5–9 This report focuses attention on
the interaction between smoking status and outcomes after
acute ischemic strokethe so-called smoker’s paradoxand
highlights the challenges of distinguishing residual and
unmeasured confounding from true associations in cardio-
vascular disease epidemiology.
While the smoker’s paradox in cardiovascular disease
patients has been partly explained by younger age of onset
and fewer coexisting high-risk features in patients with AMI
who are current smokers, a small number of studies have
shown that the residual lower mortality risk persists despite
comprehensive covariate adjustment.2,10–13 Aune et al14
published a systematic review in 2011 reporting that the
paradox was observed in some studies of AMI patients in the
prethrombolytic and thrombolytic era, whereas no studies of a
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contemporary population with acute coronary syndrome have
found evidence for such a paradox. Furthermore, some
angiographic studies have demonstrated that coronary artery
occlusion in smokers is predominantly caused by thrombosis
and thus may have a better response to spontaneous or
therapeutic thrombolysis.15–19
The etiology of myocardial infarction and acute ischemic
stroke is similar in terms of occlusion leading to ischemia.
Similar risk factors predispose patients to ischemic stroke as
that of myocardial infarction. Despite the plethora of data
exploring smokers’ post-AMI survival advantage, the role of
smoking in the short-term prognosis after acute ischemic
stroke remains to be clariﬁed.
Saver et al analyzed the National Institute of Neurological
Disorders and Stroke (NINDS) tissue plasminogen activator
(tPA) stroke trials data which suggested that recent smokers
with acute ischemic stroke who received intravenous (IV)
thrombolysis experienced a better early outcome than
nonsmokers. Furthermore, the study suggested that fewer
thrombolysis-treated smokers may exhibit global disability at
90 days and that thrombolysis-treated smokers may have
better survival rates at 1 year than thrombolysis-treated
nonsmokers.20
These and other observations motivated us to perform a
retrospective analysis of our acute ischemic stroke (AIS)
patients’ database and to evaluate if a similar association of
smoking and short-term outcomes was present. The objective
of this study was to examine the associations between
demographic and clinical characteristics, presentation,
in-hospital treatment, and mortality among patients with
and without active cigarette smoking (any cigarette use in the
past year) who were hospitalized with AIS.
Methods
Patients Population
Using our hospital’s Get with the Guidelines-Stroke (GWTG-
Stroke) registry, we analyzed patients consecutively admitted
with AIS. GWTG-Stroke is an ongoing, voluntary, continuous
registry and performance improvement initiative. It collects
patient-level data on characteristics, diagnostic testing,
treatments, adherence to quality measures, and in-hospital
outcomes for those hospitalized with AIS. Trained hospital
personnel ascertain consecutive patients admitted with
stroke by either prospective clinical identiﬁcation, retrospec-
tive identiﬁcation using International Classiﬁcation of
Diseases (ICD)-9 discharge codes, or a combination of both.
Prospective identiﬁcation includes regular surveillance of
emergency department records (ie, presenting symptoms and
chief complaints), ward census logs, and/or neurological
consultations. The eligibility of each acute stroke is conﬁrmed
at chart review before abstraction. After abstraction by
trained personnel at the hospital, deidentiﬁed patient data are
entered into the GWTG-Stroke database using a Web-based
patient management tool (PMT, Outcome). Data abstracted
included patient demographics, medical history and comor-
bidities, calendar year, initial head computerized tomography
ﬁndings, in-hospital treatment and events, discharge treat-
ment and counseling, mortality, and discharge destination.
After excluding patients with possible transient ischemic
attacks (TIAs) and stroke mimics, our cohort consisted of
4305 AIS patients admitted from March 2002 until December
2011. Data on demographics, comorbidities, NIHSS at the
time of admission, in-hospital interventions, length of stay,
and mortality were collected and analyzed.
Deﬁnitions
Smoking
The study population was divided into 2 groups based on their
smoking status. Information about smoking status was
abstracted from the medical record by a trained abstractor
and classiﬁed according to the GWTG-Stroke coding instruc-
tions which are derived from the Medicare deﬁnition of
smoking status. The 2 groups consisted of current smokers
(any cigarette use within the year preceding the stroke) versus
nonsmokers (either never smokers or those who had been
abstinent for >1 year prior to stroke). The data do not
distinguish between the 2 subtypes of nonsmokers.
GWTG-stroke in-hospital measures
Inpatient management including performance of dysphagia
screening, use of early antithrombotics and DVT/PE prophy-
laxis were all recorded at the patient level according to GWTG-
Stroke deﬁnitions. The absolute rates of these interventions
are listed in Table 1 among all patients admitted, without
exclusions for ineligibility.
Outcome
The primary outcome of interest for this study was in-hospital
mortality, which was deﬁned as patients who expired during
their stay at the hospital or were discharged to hospice for
end-of-life care. We had in-hospital mortality data for all 4305
patients included in the study.
Statistical Analysis
The sample was divided into the 2 aforementioned groups
and frequencies with percentages were generated for the
dichotomous variables (gender, race, comorbidities, in-hos-
pital interventions, and mortality). Values for age were
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expressed as meanSD and that for NIHSS as median with
interquartile ranges. Pearson chi-square was employed for
categorical variables to compare the baseline characteristics
of the 2 groups. For continuous variables, we used indepen-
dent t-test for age and Wilcoxon rank sum test for
comparative analysis of NIHSS between smokers and
nonsmokers. Unadjusted univariate OR with 95% CIs were
computed for all variables, but reported for only those
variables that were signiﬁcant in univariate testing. All tests
of statistical signiﬁcance were 2-tailed and were considered
to be signiﬁcant at a 0.05 level of statistical signiﬁcance,
unless otherwise speciﬁed.
Multivariable logistic regression analysis was employed
to determine independent associations between in-hospital
Table 1. Baseline Characteristics, In-Hospital Treatments, and Mortality of Patients Admitted With Acute Ischemic Stroke
According to Smoking Status
Smokers (n=703) Nonsmokers (n=3602) P Value
Age, y 59.613.8 70.814.8 <0.001
Gender (male) 422 (60.0%) 1923 (53.4%) <0.001
Race (white) 641 (91.2%) 3151 (87.5%) 0.01
Medical history
HTN 387 (55.0%) 2525 (70.1%) <0.001
DM 122 (17.4%) 883 (24.5%) <0.001
HL 246 (35.0%) 1497 (41.6%) <0.001
CAD 101 (14.4%) 848 (23.5%) <0.001
Previous stroke/TIA 80 (11.4%) 482 (13.4%) 0.15
A Fib 60 (8.5%) 876 (24.3%) <0.001
PVD 46 (6.5%) 171 (4.7%) 0.05
NIHSS (n=657 vs 3343) 4 (2 to 11) 5 (2 to 13) <0.001
Median (IV tPA cohort) 13 13 0.23
tPA (all types) 100 (14.2%) 683 (19.0%) <0.001
tPA at MGH 39 (5.5%) 252 (7.0%) 0.16
tPA at OSH 61 (8.7%) 431 (12.0%) 0.01
IA therapy at MGH 30 (6.6%) 213 (8.1%) 0.28
GWTG measure adherence
Early antithrombotics 640/684 (93.6%) 3183/3446 (92.4%) 0.07
Dysphagia screening 439/634 (69.2%) 2366/3241 (73.0%) 0.08
DVT/PE prophylaxis* 525/532 (98.7%) 2796/2849 (98.1%) 0.67
Complications
Pneumonia* 84/685 (12.3%) 333/3517 (9.5%) 0.03
UTI* 12/270 (4.4%) 143/1869 (7.7%) 0.06
Length of stay (days) 5.04.3 4.84.2 0.22
Unable to ambulate at D/C 85 (12.1%) 612 (17.0%) 0.002
Discharge disposition
Home 336 (47.8%) 1370 (38.0%) <0.001
IRF 289 (41.1%) 1496 (41.5%)
SNF 32 (4.6%) 259 (7.2%)
Expired 46 (6.5%) 477 (13.2%)
In-hospital mortality 46 (6.5%) 477 (13.2%) <0.001
HTN indicates hypertension; DM, diabetes mellitus; HL, hyperlipidemia; CAD, coronary artery disease; TIA, transient ischemic attack; A Fib, atrial ﬁbrillation; PVD, peripheral vascular
disease; tPA, tissue plasminogen activator; MGH, Massachusetts General Hospital; OSH, Outside Hospital; GWTG, Get with the Guidelines; DVT, deep vein thrombosis; D/C, discharge;
NIHSS, NIH Stroke Score; IV, intravenous; IA, intraarterial; UTI, urinary tract infection; IRF, inpatient rehabilitation facility; SNF, skilled nursing facility.
*Variables with rates of missing >10% (UTI, 49.5%; DVT/PE, 12.5%).
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mortality and all covariables signiﬁcant in univariate analysis
(P<0.1). Variables that reﬂect processes of care during
hospitalization or complications were not included in the
model. To avoid any bias associated with variable selection,
we repeated the multivariable model with all covariates.
We also carried out secondary analyses by restricting our
study cohort to evaluate if the association of smoking with
in-hospital mortality persists in (1) patients with ﬁrst ever
stroke, excluding those with a prior history of stroke, (2)
patients without a prior history of CAD, (3) patients who
received IV tPA, and (4) patients stratiﬁed by age at admission
(≤60 and >60 years). Statistical analyses were performed
using the software SPSS, version 20.0.
Results
Characteristics of the Study Population
We indentiﬁed a total of 4305 AIS patients, out of whom 703
(16.3%) were current smokers. Mean age was observed to be
69.115.2 years; 54.5% of patients were male and 88.1%
were white. Vascular comorbidities were frequent with
hypertension being the most common in 67.6% of AIS
patients, hyperlipidemia (HL) in 40.5%, diabetes mellitus
(DM) in 23.3%, CAD in 22.0% and peripheral vascular disease
(PVD) in 5.0%. Atrial ﬁbrillation (Aﬁb) was seen in 21.7% of AIS
patients.
A total of 244 (5.7%) of patients with AIS had a prior
episode of stroke. Eighteen percent of patients were treated
with IV, while 6% received intra-arterial tPA. Most of the
patients admitted were given early antithrombotics (92.6%),
underwent dysphagia screening (72.4%) before commence-
ment of oral intake and had DVT/PE prophylaxis (98.4%)
within 48 hours of arrival. Common complications recorded
were in-hospital pneumonia in 10.0% (417/4202) and urinary
tract infection (UTI) in 7.2% (155/2139).
As expected, the groups of smokers and nonsmokers
differed signiﬁcantly in many characteristics, as shown in
Table 1. Smokers, on average, were 10 years younger and
were more often males. They were also more frequently white
with a higher percentage of peripheral vascular disease.
Smokers had fewer risk factors for stroke as compared to
nonsmokers. They were signiﬁcantly less likely to have a
history of hypertension (HT), DM, HL, CAD, and Aﬁb. Smokers
presented with a 1-point lower median NIHSS (4 versus 5)
which was signiﬁcant when compared to nonsmokers. A
greater percentage of nonsmokers received thrombolysis (IV
or intraarterial). The absolute rates of dysphagia screening,
antithrombotic use and DVT prevention were similar for the 2
groups. Smokers were more likely to experience hospital-
acquired pneumonia, while UTI was more common in
nonsmokers.
In-Hospital Mortality Rates
Smoking was associated with lower all-cause in-hospital
mortality. Only 6.5% of smokers died during their stay as
compared with 13.2% of nonsmokers. In univariate analysis,
smoking was associated with lower unadjusted OR for death
of 0.46 (95% CI of 0.34 to 0.63 [P<0.001]). Smokers also had
more favorable discharge destination, with a greater percent-
age going to home or to an inpatient rehabilitation facility.
Univariate analysis also demonstrated that age was
strongly related to in-hospital mortality. The mean agestan-
dard deviation of the patients with in-hospital mortality was
signiﬁcantly higher compared to the patients who survived
(67.915.1 versus 77.112.9; P<0.001). The results of
univariate analysis of in-hospital mortality rates, according to
the baseline characteristics, are shown in Table 2. Other
positive predictors of mortality included female gender, white
race, and presence of HT, CAD, Aﬁb, PVD, higher NIHSS, and
in-hospital pneumonia. Intervention with IV tPA and smoking
were the only 2 factors associated with lower mortality on
univariate analysis.
All signiﬁcant univariate predictors of in-hospital mortality
were included in a logistic regression model in order to
examine their independent association with in-hospital mor-
tality. Older age, history of cardiovascular disease, white race,
and higher NIHSS at presentation remained signiﬁcantly
associated with higher of mortality, while smoking and IV tPA
use were associated with lower in-hospital mortality. A
signiﬁcant change in the rates of smoking was observed over
the study period. It increased from 17.4% in 2001 to 22.0% in
2005 and then subsequently dropped to 11.0% in 2011 (P
value for trend <0.001). In-hospital mortality varied from
11.5% in 2003 to 14.5% in 2011. Since the rates of smoking
varied over the study period, we included a calendar year term
in the ﬁnal model. The adjusted OR for in-hospital mortality
associated with smoking was 0.64 (0.42 to 0.96; P=0.03). A
repeat analysis using all covariates did not change the
adjusted OR for smoking 0.647 (0.43 to 0.96).
Secondary Analyses
First ever stroke
The favorable association of smoking with lower in-hospital
mortality persisted in the sub-group of patients with ﬁrst ever
index stroke. When a total of 244 patients with prior ischemic
stroke were excluded from the analysis (28 smokers, 216
nonsmokers) the observed unadjusted OR remained signiﬁ-
cant for the association between smoking and mortality (OR
0.45 [0.33 to 0.62]; P<0.001). In hospital mortality was 6.4%
(n=43) for smokers as compared to 13.1% (n=445) for
nonsmokers (P<0.001).
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Cohort without coronary artery disease
Another model consisting of patients without any history of
CAD (n=3356) was created to account for any confounding
effect of CAD on mortality (n=3356; 602 smokers, 2754
nonsmokers). In-hospital mortality was 5.6% (n=34) for
smokers as compared to 11.5 % (n=316) for nonsmokers
(P<0.001). Similar results were seen with smoking in
patients without CAD (unadjusted OR 0.46 [0.32 to 0.67];
P<0.001).
Thrombolysis
Out of the 4305 patients included in this study, 783 received
IV tPA of which 14.2% (100) were smokers. As shown in
Table 1, nonsmokers were more likely to receive IV tPA as
compared to smokers. Unadjusted in-hospital mortality
among smokers was signiﬁcantly lower in thrombolysed
patients as well, when compared to nonsmokers (8.0% versus
20.6%; P=0.003). On multivariable analysis, even a stronger
association was observed with OR 0.33 ([0.16 to 0.71];
P=0.004). Positive predictors of mortality in this sub-group
were similar to those in the total cohort and included age (OR
1.06 [1.04 to 1.08]), HT (OR 1.84 [1.21 to 2.80]), CAD
(OR 2.54 [1.74 to 3.70]), Aﬁb (OR 2.32 [1.60 to 3.37]), DM
(OR 1.51 [0.99 to 2.30]), increasing NIHSS (OR 1.20 per point
[1.15 to 1.24]), and development of hospital-acquired pneu-
monia (OR 1.68 [1.02 to 2.76]). The only factor associated
with lower odds of mortality was smoking. In the cohort of
patients who did not receive IV tPA, smoking was still
signiﬁcantly associated with lower mortality, with OR of 0.52
(0.37 to 0.73; P<0.001).
Different age strata
Since smokers with AIS were signiﬁcantly younger than
nonsmokers, we divided the study population into 2 cohorts
based on the median age of smokers (60 years). In total
there were 1206 patients with age ≤60 years and of these
29.6% (n=357) were smokers. In-hospital mortality was lower
for smokers versus nonsmokers ≤60 years (3.4% versus 6.2%;
P=0.04) with an OR 0.52 (0.28 to 0.99; P=0.046) and in those
>60 years (9.8% versus 15.4%, P<0.001) with an OR 0.60
(0.41 to 0.87; P<0.001).
Discussion
This study, based on the analysis of all consecutively admitted
AIS patients in our major regional stroke center over the past
9 years, demonstrated that smoking is associated with lower
in-hospital mortality after AIS. This ﬁnding persisted even
after extensive adjustment for measured covariates and
temporal trends. These ﬁndings extend the “smokers para-
dox,” which has been previously described for acute coronary
syndromes and acute heart failure, to patients hospitalized
with AIS, and provide important insights into the relationship
of smoking to the age of patients at stroke onset and other
demographic and clinical characteristics.
Cigarette smoking is a major risk factor for AIS. Prior
studies estimate that smoking nearly doubles the risk of
ischemic stroke. Consistent with this risk, patients who were
current cigarette smokers in this study presented with stroke
at substantially younger ages compared to current nonsmok-
ers. They were also less likely to have other traditional risk
Table 2. Factors Signiﬁcantly Associated With In-Hospital Mortality in Univariate Analysis and Multivariable Logistics Regression
Model
Unadjusted OR 95% Conﬁdence Interval Adjusted OR 95% Conﬁdence Interval
Age (per year) 1.05 (1.04 to 1.06) 1.03 (0.43 to 0.96)
Gender (female) 1.30 (1.08 to 1.56) — —
Race (white) 1.43 (1.04 to 1.96) 1.55 (1.04 to 2.32)
Comorbidities
Hypertension 1.36 (1.10 to 1.66) — —
CAD 1.92 (1.57 to 2.34) 1.70 (1.30 to 2.21)
A Fib 2.69 (2.22 to 3.26) — —
PVD 1.47 (1.02 to 2.13) — —
NIHSS 1.20 (1.19 to 1.22) 1.21 (1.19 to 1.23)
IV tPA 0.51 (0.41 to 0.62) 0.71 (0.55 to 0.93)
Smoking 0.46 (0.34 to 0.63) 0.64 (0.42 to 0.96)
Pneumonia 2.62 (2.04 to 3.36) — —
OR indicates odds ratio; CAD, coronary artery disease; A Fib, atrial ﬁbrillation; PVD, peripheral vascular disease; NIHSS, NIH Stroke Score; IV, intravenous; tPA, tissue plasminogen
activator.
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factors for stroke. These baseline differences have been
reported in the vast majority of previous large-scale studies
examining the smokers’ paradox, especially in acute coronary
syndrome (ACS) patients.16,21–23
Differences in health outcomes at discharge in this study
by smoking status may reﬂect differences in the character-
istics of patients with AIS by smoking status. In previous
studies, older age had been consistently regarded as the most
important factor inﬂuencing early prognosis after AIS.24,25 In
our study, cigarette smokers were 10 years younger com-
pared to nonsmokers, and age-related differences contributed
to the unadjusted survival differences. Cigarette smokers
were also most likely to be males. An independent inﬂuence
of gender on early mortality after AIS has been well
documented by Smith et al25 in a cohort of 274 988 ischemic
stroke patients. Despite the adjustment for age and gender,
the reduced mortality associated with smoking persisted. In
the literature exploring the effect of smoking on mortality
after myocardial infarction, the paradox does not hold true
when comparing longer-term mortality in smokers who quit
versus smokers who continued smoking after the index
event.26 The latter group had a signiﬁcantly higher mortality,
supporting the notion that smoking has deleterious effects in
the cardiovascular system. This fact demonstrates that
“paradoxes” like this do not prove that a risk factor may
also be in some ways protective, but simply identify an
association. It is just as likely that among smokers there is a
fundamentally different set of pathophysiologic mechanisms
contributing to stroke risk and that comparison between the
groups therefore remains confounded despite measured
covariate adjustment. This distinction requires a large cohort
of smokers in whom the quantitative smoking exposure is well
characterized, and rates of adverse events are measured both
in-hospital and longitudinally.
Cigarette smoking has been associated by Vlietstra et al27
with less extensive and less severe CAD in a cohort of 15 298
patients with established CAD, who were enrolled in the
Coronary Artery Surgery Study. Despite the lack of similar
data for AIS patients, lower NIHSS observed for smokers may
suggest that this ﬁnding of decreased severity of the index
event holds true for stroke patients as well. In multivariable
logistic regression, we included NIHSS as a covariate to adjust
for difference in severity on presentation of the 2 groups.
Smokers were still observed to have a better prognosis after
accounting for NIHSS.
Smoking has been associated with increased hematocrit,
platelet activation and aggregation, vasoconstriction, increa-
sed circulating levels of ﬁbrinogen, thrombin generation, and
impaired endogenous ﬁbrinolytic capacity.28–30 As a result,
the pathogenesis of vascular occlusions may be more
thrombogenic than atherogenic in smokers, particularly those
with fewer biomarkers of traditional atherosclerosis risk
factors, whereas in nonsmokers, occlusion may be more
frequently due to rupture or ulceration of atheromatous
plaque with formation of platelet-rich clot. All of this may
reﬂect a greater susceptibility of cerebral thrombi to spon-
taneous or therapeutic thrombolysis in smokers, an effect
which was observed in our study reﬂected by lower OR for
mortality among smoking in the cohort of patients treated
with IV tPA.
Alternatively, it may be that the abrupt cessation of
smoking during AIS improves outcomes among smokers, or
that medication used to assist in abstinence, such as nicotine
replacement, may have some protective role in hospitalized
patients with stroke.
Chronic changes in vasomotor tone and episodic hypoxia
might lead to ischemic preconditioning in smokers, as well as
the development of improved small vessel cerebral collaterals
and better cerebral perfusion. These and other changes to
brain metabolism might limit the initial injury and inﬂuence
stroke progression and mortality. These avenues warrant
further investigation.
This apparent smoker’s paradox in AIS patients should not
be interpreted as a beneﬁt of cigarette smoking. The
hazardous effects of smoking are manifested as the occur-
rence of stroke in patients years earlier than might otherwise
have occurred. It is likely that our models have been unable to
completely control for these differences in age of onset,
despite our best attempts in the reported sensitivity analyses.
Intensive efforts to encourage smoking cessation as a primary
and secondary preventive measure for stroke should remain a
very high priority. Effective smoking prevention and cessation
methods should be implemented as vigorously as other
guideline-recommended therapies for the prevention of
stroke. In fact, the smoker’s paradox might just be an
apparent one; on further dissection, smokers are getting
milder strokes years earlier than they might otherwise
experience cerebral ischemia, and there is no evidence that
early milder strokes are in anyway protective of later, more
disabling age-appropriate strokes. This apparent paradox
deserves much more attention.
Our present analysis of smoking and in-hospital mortality
has some important limitations. We used the GWTG-Stroke
deﬁnition of “smoking,” which is derived from Medicare
reporting and quality programs that deﬁne smokers as those
who have used cigarettes in the past year. This is due to the
high rates of recidivism seen in this cohort. Therefore, our
cohort of smokers is heterogeneous and includes current
heavy smokers, recent light smokers, and individuals who are
not currently smoking but have done so in the past year. The
data could be missing some baseline clinical variables and
in-hospital complications, so we cannot exclude the possibility
that unmeasured or residual confounding may explain some
or all of our ﬁndings. Because smoking dose is not usually in
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the medical record and therefore we do not have a
quantiﬁcation of smoking exposure (ie, “smoking dose”),
our ability to assess correlations between smoking and the
age of stroke onset or presence of polyvascular disease is
limited. This may contribute to our inability to distinguish a
true protective effect from the more likely residual confound-
ing. Smokers may be more likely to have small vessel stroke
than cardioembolic or other sub-types, as compared to
nonsmokers, and this may be related to stroke outcomes.
Because the stroke subtype is not captured in the database
analyzed for this study, we are unable to adjust for this
ﬁnding. Patients reporting of smoking status may not have
been reliable in all cases. No quantitative measures were
conducted to evaluate the biologic effects of smoking in
patients with AIS such as thrombotic factors, endothelial
function, and systemic inﬂammatory markers. Larger multi-
center studies are needed to conﬁrm the ﬁnding, investigate
a possible difference in stroke sub-type between the 2
groups, and assess if the mortality beneﬁt persists at 30 days
and 1 year post discharge.
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